Study of Early Lymphopheresis for Relapsed/Refractory DLBCL Sheds Light on CAR-T Efficacy
Researchers explored early lymphopheresis for CD19-based chimeric antigen receptor T-cell therapy for relapsed/refractory DLBCL.
Diagnosis & Disease Information
CAR T-Cells May Be Safe in Non-Transplant Eligible Patients With Large B-Cell Lymphoma
Researchers sought to determine whether CAR-T therapy would be a viable option for patients with relapsed/refractory large B-cell lymphoma.
Young Cancer Survivors Have Increased Risk for HPV-Linked Subsequent Cancer
Significantly increased risk seen for any HPV-associated subsequent malignant neoplasms and oropharyngeal neoplasms.
High CMR Rates Seen With Nivolumab Plus Brentuximab Vedotin in CAYA Relapsed/Refractory Hodgkin Lymphoma
Researchers sought to determine whether combining nivolumab plus brentuximab vedotin would improve response rates in CAYAs with Hodgkin lymphoma.
Lenalidomide Maintenance Not Recommended After ASCT in High-Risk Non-Hodgkin Lymphoma
Researchers sought to determine whether lenalidomide maintenance would improve outcomes in patients with high-risk non-Hodgkin lymphoma who receive HDT/ASCT .
ART and Pediatric Cancer: Risk May Vary by Method Used, Cancer Type
Research has suggested that ART may increase the risk of pediatric cancers, but studies have shown conflicting results, and questions remain.
Survey Reveals Physician Preferences for Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine physician preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma in the third line setting.
Genetic Variants and Methotrexate in Primary Central Nervous System Lymphoma
Researchers sought to determine the role of certain genetic variants as biomarkers in primary central nervous system lymphoma.
Pediatric Cancer Survivors Have 4-Fold Higher Risk of Death 40 Years After Diagnosis
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
Pembrolizumab Plus ICE Deemed Effective in Relapsed/Refractory Hodgkin Lymphoma
Pembrolizumab plus ICE chemotherapy appears effective as second-line treatment in patients with transplant-eligible Hodgkin lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...